Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Q2 revenue rises to $194.4 million from $163.8 million; 2025 guidance modified

Mixed Impact 4 of 5 earnings Written later

Corcept reported second quarter 2025 revenue of $194.4 million, up from $163.8 million a year earlier, but net income was $35.1 million versus $35.5 million and diluted earnings per share fell to $0.29 from $0.32. The company modified its 2025 revenue guidance to $850 million to $900 million and said demand outpaced its specialty pharmacy vendor's capacity, which it expects to ease as a second pharmacy comes online.

Key points

  • Q2 2025 revenue $194.4 million vs. $163.8 million in Q2 2024
  • Net income $35.1 million vs. $35.5 million; diluted EPS $0.29 vs. $0.32
  • Selling, general and administrative expense $103.9 million vs. $66.9 million a year earlier
  • 2025 revenue guidance modified to $850 million to $900 million; cash and investments $515.0 million at June 30, 2025

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECJul 31, 2025, 4:07 PM ET
Accession number0001628280-25-036999

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.